There are approximately 7000 rare diseases affecting 30 million individuals in the United States and up to 250 million individuals worldwide. The unmet medical need for individuals living with these conditions has made this a very active area for research and development. Precision’s Phil Cyr discusses how patients and caregivers can be a catalyst for rare disease innovation.
This article was originally published on This Month in Transformative Medicine on October 17, 2023
The current standard of cancer care has saved many lives, but these methods often come with incredibly difficult side effects. Advancements in technology have brought new options to cancer care that hope to provide meaningful outcomes while minimizing the impact to the patient’s quality of life.
In this white paper Anshul Mangal, President of Project Farma (PF) & Precision ADVANCE, and Sumit Verma, Co-founder and Partner at Orchestra Life Sciences, discuss the power and potential of radioligand therapies and its impact on the treatment of a number of cancers.
How can our industry address the root causes for the current cancer drug shortages, and how can we prepare and avoid these shortages? Anshul Mangal, President of Project Farma and Precision ADVANCE, sat down with PharmExec.com to share answers.
Sponsored by Precision ADVANCE, this Endpoints webinar will convene industry leaders to discuss the current state of the industry, and the future of advanced therapies including innovations in research and development, going from treating rare diseases to prevalent conditions, continued investment, and next-generation technologies. The panelists will also discuss manufacturing and talent bottlenecks, and innovative reimbursement payment models. This discussion will be moderated by Anshul Mangal: President (Precision ADVANCE & Project Farma), and included insights from Dan Kirby: Chief Commercial Officer (Orca Bio), Deborah Phippard: CSO (Precision for Medicine), and additional panelists.
Download the latest IRA Special Edition Update — Medicare Drug Price Negotiation: First 10 Drugs Announced. These drugs accounted for $50.5 billion in Medicare Part D spending from June 2022 to May 2023. So what happens next?
The PV&H October Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
Precision will be at HLTH 2023, October 8 – 11, in Las Vegas, NV. Connect with our team of experts as they lead meaningful discussions and attend networking events focused on innovation and transformation for better patient health and treatment outcomes.
Connect with one our experts!
Precision’s Phil Cyr will be the presenting at this year’s Association for Value-Based Cancer Care 2023 Educational Summit & Program, October 18 – 20, NYC, NY. This exclusive invitational forum provides invaluable time with more than 200 diverse experts representing every stakeholder of the cancer care ecosystem.
Don’t miss an opportunity to celebrate groundbreaking science and network with industry leaders!
You can register for the Association for Value-Based Cancer Care 2023 Educational Summit & Program:
Precision will be at this year’s Meeting on the Mesa, October 10-12, 2023, in Carlsbad, CA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for cell and gene therapies.
Connect with our Advanced Therapy experts
You can register for Meeting on the Mesa below:
The PV&H September Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
